A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Status: Recruiting
Phase:
Diagnosis: Leukemia/MDS
NCT ID: NCT01564784 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-528

 

This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.

 

Conducting Institutions:
Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital

Overall PI:
Daniel DeAngelo, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:
Philip Amrein, MD, Massachusetts General Hospital

Contacts:
Dana-Farber Cancer Institute: Ilene Galinsky, 617-632-3902, igalinsky@partners.org
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100

Eligibility Criteria

Inclusion Criteria: - CD22 expression - Adequate liver and renal functions Exclusion Criteria: - Isolated extramedullary disease - Active Central Nervous System [CNS] disease
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms